T. Rowe Price Associates’s Syneos Health, Inc. Class A Common Stock SYNH Stock Holding History

T. Rowe Price Associates’s Portfolio SYNH Stock Details SYNH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-39,783	Closed	-$1.68M	–	2925
2023 Q2	$1.68M	Buy	39,783 +973	+3%	+$39.3K	﹤0.01%	1553
2023 Q1	$1.38M	Sell	38,810 -5,919	-13%	-$215K	﹤0.01%	1626
2022 Q4	$1.64M	Sell	44,729 -545	-1%	-$21.5K	﹤0.01%	1542
2022 Q3	$2.13M	Buy	45,274 +4,346	+11%	+$281K	﹤0.01%	1431
2022 Q2	$2.93M	Sell	40,928 -2,009	-5%	-$147K	﹤0.01%	1514
2022 Q1	$3.48M	Buy	42,937 +3,872	+10%	+$328K	﹤0.01%	1540
2021 Q4	$4.01M	Sell	39,065 -1,686	-4%	-$162K	﹤0.01%	1527
2021 Q3	$3.56M	Buy	40,751 +1,718	+4%	+$156K	﹤0.01%	1561
2021 Q2	$3.49M	Buy	39,033 +1,257	+3%	+$106K	﹤0.01%	1581
2021 Q1	$2.87M	Buy	37,776 +5,964	+19%	+$450K	﹤0.01%	1596
2020 Q4	$2.17M	Buy	31,812 +281	+0.9%	+$17.5K	﹤0.01%	1611
2020 Q3	$1.68M	Sell	31,531 -4,218	-12%	-$251K	﹤0.01%	1600
2020 Q2	$2.08M	Buy	35,749 +423	+1%	+$22.7K	﹤0.01%	1526
2020 Q1	$1.39M	Sell	35,326 -1,717	-5%	-$100K	﹤0.01%	1600
2019 Q4	$2.2M	Buy	37,043 +2,469	+7%	+$133K	﹤0.01%	1575
2019 Q3	$1.84M	Buy	34,574 +301	+0.9%	+$15.4K	﹤0.01%	1596
2019 Q2	$1.75M	Sell	34,273 -330,907	-91%	-$15.4M	﹤0.01%	1632
2019 Q1	$18.9M	Buy	365,180 +131	+0%	+$6.35K	﹤0.01%	1191
2018 Q4	$14.4M	Sell	365,049 -4,430	-1%	-$206K	﹤0.01%	1239
2018 Q3	$19M	Sell	369,479 -27,620	-7%	-$1.35M	﹤0.01%	1246
2018 Q2	$18.6M	Sell	397,099 -8,843	-2%	-$366K	﹤0.01%	1225
2018 Q1	$14.4M	Sell	405,942 -142,307	-26%	-$5.57M	﹤0.01%	1277
2017 Q4	$23.9M	Sell	548,249 -17,554	-3%	-$820K	﹤0.01%	1125
2017 Q3	$29.6M	Buy	565,803 +36,678	+7%	+$2.05M	0.01%	1048
2017 Q2	$31M	Buy	529,125 +47,089	+10%	+$2.45M	0.01%	1009
2017 Q1	$22.1M	Sell	482,036 -32,334	-6%	-$1.61M	﹤0.01%	1119
2016 Q4	$27.1M	Buy	514,370 +13,865	+3%	+$671K	0.01%	1028
2016 Q3	$22.3M	Buy	500,505 +146,735	+41%	+$6.36M	﹤0.01%	1094
2016 Q2	$13.5M	Buy	353,770 +2,695	+0.8%	+$118K	﹤0.01%	1225
2016 Q1	$14.5M	Buy	351,075 +139,845	+66%	+$5.76M	﹤0.01%	1180
2015 Q4	$10.2M	Buy	+211,230	New	+$9.4M	﹤0.01%	1278

Other funds holding SYNH

Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Natixis Advisors Boston, Massachusetts $71.9B AUM 28.03% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Nomura Asset Management Tokyo, Japan $38.8B AUM 30.94% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

CFB

Cullen/Frost Bankers San Antonio, Texas $8.81B AUM 22.47% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

T. Rowe Price Associates's SYNH Position: Q3 2023 in Review

T. Rowe Price Associates sold out of Syneos Health, Inc. Class A Common Stock (SYNH) in Q3 2023, closing a stake of 39,783 shares — an estimated $1.68M sold.

T. Rowe Price Associates first reported a position in SYNH in Q4 2015 and held it in 31 quarters. The position peaked at $31M in Q2 2017. 10 funds tracked by Wall St. Rank hold SYNH as of Q3 2023.

T. Rowe Price Associates reported no remaining Syneos Health, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
T. Rowe Price Associates sold 39,783 Syneos Health, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.68M.
T. Rowe Price Associates first reported a position in Syneos Health, Inc. Class A Common Stock in Q4 2015 and held it in 31 quarters.
T. Rowe Price Associates's Syneos Health, Inc. Class A Common Stock position peaked at $31M in Q2 2017.
10 funds tracked by Wall St. Rank held Syneos Health, Inc. Class A Common Stock as of Q3 2023.

Based on T. Rowe Price Associates's 13F filing for Q3 2023, filed 14 Nov 2023.